Alcohol abstinence ameliorates the dysregulated immune profiles in patients with alcoholic hepatitis: A prospective observational study

Wei Li, Tohti Amet, Yanyan Xing, Dennis Yang, Suthat Liangpunsakul, Puneet Puri, Patrick S. Kamath, Arun J. Sanyal, Vijay H. Shah, Barry P. Katz, Svetlana Radaeva, David W. Crabb, Naga Chalasani, Qigui Yu – 2 May 2017 – Alcoholic hepatitis (AH) develops in only a small proportion of heavy drinkers. To better understand the mechanisms underlying this disparity, we conducted a study to define the relationship between AH development and dysregulated immune responses that might be ameliorated by alcohol abstinence.

Main drivers of outcome differ between short term and long term in severe alcoholic hepatitis: A prospective study

Alexandre Louvet, Julien Labreuche, Florent Artru, Alexis Bouthors, Benjamin Rolland, Pierre Saffers, Julien Lollivier, Elise Lemaître, Sébastien Dharancy, Guillaume Lassailly, Valérie Canva‐Delcambre, Alain Duhamel, Philippe Mathurin – 29 April 2017 – Understanding the mechanisms of outcome according to the time frame can help optimize the therapeutic development in severe alcoholic hepatitis.

Main drivers of outcome differ between short term and long term in severe alcoholic hepatitis: A prospective study

Alexandre Louvet, Julien Labreuche, Florent Artru, Alexis Bouthors, Benjamin Rolland, Pierre Saffers, Julien Lollivier, Elise Lemaître, Sébastien Dharancy, Guillaume Lassailly, Valérie Canva‐Delcambre, Alain Duhamel, Philippe Mathurin – 29 April 2017 – Understanding the mechanisms of outcome according to the time frame can help optimize the therapeutic development in severe alcoholic hepatitis.

Vaccines targeting preS1 domain overcome immune tolerance in hepatitis B virus carrier mice

Yingjie Bian, Zheng Zhang, Zhichen Sun, Juanjuan Zhao, Danming Zhu, Yang Wang, Sherry Fu, Jingya Guo, Longchao Liu, Lishan Su, Fu‐Sheng Wang, Yang‐Xin Fu, Hua Peng – 26 April 2017 – Strong tolerance to hepatitis B virus (HBV) surface antigens limits the therapeutic effect of the conventional hepatitis B surface antigen (HBsAg) vaccination in both preclinical animal models and patients with chronic hepatitis B (CHB) infection. In contrast, we observed that clinical CHB patients presented less immune tolerance to the preS1 domain of HBV large surface antigen.

Polo‐like‐kinase 1 is a proviral host factor for hepatitis B virus replication

Ahmed Diab, Adrien Foca, Floriane Fusil, Thomas Lahlali, Pascal Jalaguier, Fouzia Amirache, Lia N'Guyen, Nathalie Isorce, François‐Loïc Cosset, Fabien Zoulim, Ourania Andrisani, David Durantel – 26 April 2017 – Chronic hepatitis B virus (HBV) infection is a major risk factor for hepatocellular carcinoma (HCC) and current treatments for chronic hepatitis B and HCC are suboptimal. Herein, we identified cellular serine/threonine Polo‐like‐kinase 1 (PLK1) as a positive effector of HBV replication.

Subscribe to